Cargando…
Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
INTRODUCTION: Sodium selenate is a potential disease-modifying treatment for Alzheimer’s disease (AD) which reduces hyperphosphorylated tau through activation of the protein phosphatase 2A enzyme. We have shown sodium selenate to be safe and well tolerated in a 24-week, phase 2a double-blind placebo...
Autores principales: | Vivash, Lucy, Malpas, Charles B, Hovens, Christopher M, Brodtmann, Amy, Collins, Steven, Macfarlane, Stephen, Velakoulis, Dennis, O’Brien, Terence J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679123/ https://www.ncbi.nlm.nih.gov/pubmed/34988458 http://dx.doi.org/10.1136/bmjno-2021-000223 |
Ejemplares similares
-
Sodium selenate as a therapeutic for tauopathies: A hypothesis paper
por: Dilcher, Roxane, et al.
Publicado: (2022) -
A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2022) -
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2020) -
Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
por: Vivash, Lucy, et al.
Publicado: (2021) -
Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol
por: Vivash, Lucy, et al.
Publicado: (2023)